BCAXBicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a cl…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul On August 11, Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter earnings call to deliver two headlines at once. CEO Claire Mazumdar announced she will step into a Vice Chair and Strategic Adviser role at the start of next year, handing the top job to President and Chief Operating Officer Ryan Cohlhepp. That handoff arrives just as […] | IInsider Monkey | |
 Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript Cash runway extends to 2029 as ficerafusp alfa advances toward interim analysis. | ||
 Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX) Bicara Therapeutics recently reported second-quarter 2026 results showing a wider net loss of US$55.44 million and higher loss per share, alongside filing a US$19.41 million employee stock offering shelf registration. At the same time, the company outlined a broad leadership reshuffle and ongoing preparation for possible commercialization of ficerafusp alfa, as its pivotal FORTIFI-HN01 trial in HPV-negative head and neck cancer advances toward an interim readout expected in mid-2027. We’ll... | ||
Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says Bicara Therapeutics (BCAX) pivotal Fortifi-HN01 study in first-line recurrent/metastatic HPV-negativ | MMT Newswires | |
 Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary Moby summary of Bicara Therapeutics Inc. Common Stock's Q2 2026 earnings call | ||
 Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances Bicara Therapeutics Inc. (NASDAQ:BCAX) shares gained 3. | ||
 Bicara Therapeutics Q2 Earnings Call Highlights Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of ficerafusp alfa, or FICERA, while reaffirming its cash runway into the first half of 2029. The company | ||